Published in Mol Cancer Res on November 10, 2009
Methylation markers of early-stage non-small cell lung cancer. PLoS One (2012) 1.65
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood (2011) 1.36
HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One (2013) 1.25
HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One (2012) 1.25
HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics (2011) 1.19
HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One (2012) 1.15
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma (2011) 1.07
A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening. J Virol (2012) 0.98
A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PLoS One (2012) 0.98
CancerMA: a web-based tool for automatic meta-analysis of public cancer microarray data. Database (Oxford) (2012) 0.95
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
Hitting the bull's eye: targeting HMGA1 in cancer stem cells. Expert Rev Anticancer Ther (2014) 0.86
AKNA: another AT-hook transcription factor "hooking-up" with inflammation. Cell Res (2011) 0.85
Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice. Biochem Biophys Res Commun (2013) 0.84
The high mobility group A1 molecular switch: turning on cancer - can we turn it off? Expert Opin Ther Targets (2014) 0.84
RNA-Mediated Regulation of HMGA1 Function. Biomolecules (2015) 0.83
The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology (2012) 0.82
Inhibition of testicular embryonal carcinoma cell tumorigenicity by peroxisome proliferator-activated receptor-β/δ- and retinoic acid receptor-dependent mechanisms. Oncotarget (2015) 0.79
HMGA1-pseudogenes and cancer. Oncotarget (2016) 0.79
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. BMC Genomics (2013) 0.77
HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. Neoplasia (2016) 0.76
RNA-Mediated Regulation of HMGA1 Function. Biomolecules (2015) 0.75
The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development. Curr Mol Med (2016) 0.75
TGF-β1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion. Int J Oncol (2017) 0.75
Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer. Sci Rep (2017) 0.75
Computational Detection of Stage-Specific Transcription Factor Clusters during Heart Development. Front Genet (2016) 0.75
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells. Sci Rep (2017) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst (1977) 6.91
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol (1999) 4.91
Roles of HMGA proteins in cancer. Nat Rev Cancer (2007) 3.98
Molecular biology of HMGA proteins: hubs of nuclear function. Gene (2001) 3.69
Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta (1990) 3.55
Focus on lung cancer. Cancer Cell (2002) 3.41
Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol (2001) 2.72
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 2.71
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
Increased expression of high mobility group A proteins in lung cancer. J Pathol (2006) 2.39
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Cancer invasion and metastasis: changing views. J Pathol (2008) 2.02
HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol (2000) 1.71
Structure of the human type IV collagenase gene. J Biol Chem (1990) 1.68
Serial analysis of gene expression in non-small cell lung cancer. Cancer Res (1998) 1.67
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res (1985) 1.66
Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem (1998) 1.65
Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res (1993) 1.61
On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett (1983) 1.59
The oncogenic properties of the HMG-I gene family. Cancer Res (2000) 1.57
Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene (2005) 1.53
Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A (2000) 1.47
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res (2007) 1.42
Phosphorylation by cdc2 kinase modulates DNA binding activity of high mobility group I nonhistone chromatin protein. J Biol Chem (1991) 1.39
HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res (2006) 1.28
Characterization of Encephalitozoon (Septata) intestinalis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J Eukaryot Microbiol (1996) 1.24
HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat (2002) 1.23
High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate (2004) 1.18
The molecular and cellular basis of human lung cancer. Anticancer Res (1994) 1.17
HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol (2009) 1.14
Chromosomal localization of the murine gene and two related sequences encoding high-mobility-group I and Y proteins. Genomics (1992) 1.13
CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50. Mol Cancer Res (2005) 1.10
Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res (1990) 1.07
Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res (1996) 1.03
Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther (2007) 1.02
Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res (2000) 1.00
Human pleural effusions are rich in matrix metalloproteinases. Chest (1992) 0.96
Establishment and characterization of a continuous lung squamous cell carcinoma cell line (U-1752). Anticancer Res (1981) 0.95
RPL38, FOSL1, and UPP1 are predominantly expressed in the pancreatic ductal epithelium. Pancreas (2005) 0.88
Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells. Oncogene (2004) 0.87
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 3.74
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
Loop-mediated isothermal amplification for detection of African trypanosomes. J Clin Microbiol (2003) 3.23
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood (2008) 3.05
Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res (2009) 2.77
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12
ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park) (2011) 2.11
Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost (2005) 2.07
Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis. Proc Natl Acad Sci U S A (2008) 2.06
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res (2008) 1.99
Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (2007) 1.97
Do patients drop out prematurely from exposure therapy for PTSD? J Trauma Stress (2003) 1.83
Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer (2011) 1.74
Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med (2007) 1.72
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
A combinatorial strategy for treating KRAS-mutant lung cancer. Nature (2016) 1.69
Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res (2004) 1.68
Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA (2006) 1.67
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis (2002) 1.64
Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res (2004) 1.61
A Sod2 null mutation confers severely reduced adult life span in Drosophila. Genetics (2003) 1.58
Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. Leuk Lymphoma (2013) 1.58
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther (2004) 1.54
Characterization of the ArsRS regulon of Helicobacter pylori, involved in acid adaptation. J Bacteriol (2006) 1.54
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol (2014) 1.53
Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst (2007) 1.52
A novel method of data analysis for utilization of red blood cell transfusion. Transfusion (2013) 1.52
Polymerized human Hb use in acute chest syndrome: a case report. Transfusion (2002) 1.51
Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells (2011) 1.45
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol (2006) 1.44
Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. J Biol Chem (2004) 1.44
HMGA2 participates in transformation in human lung cancer. Mol Cancer Res (2008) 1.44
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res (2007) 1.42
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem (2008) 1.41
Escherichia coli K1 RS218 interacts with human brain microvascular endothelial cells via type 1 fimbria bacteria in the fimbriated state. Infect Immun (2005) 1.41
Human Alu element retrotransposition induced by genotoxic stress. Nat Genet (2003) 1.41
Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res (2013) 1.41
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem (2011) 1.40
Mismatch repair gene mutations in renal cell carcinoma. Cancer Biol Ther (2002) 1.40
Pathogenomics of Listeria spp. Int J Med Microbiol (2007) 1.39
Temperature- and electric-field-induced inverse Freedericksz transition in a nematogen with weak surface anchoring. Phys Rev E Stat Nonlin Soft Matter Phys (2010) 1.38
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev (2003) 1.38
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med (2008) 1.37
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg (2005) 1.37
A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun (2009) 1.36
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood (2011) 1.36
The K1 capsule modulates trafficking of E. coli-containing vacuoles and enhances intracellular bacterial survival in human brain microvascular endothelial cells. Cell Microbiol (2003) 1.36
Systematic review of community-based childhood obesity prevention studies. Pediatrics (2013) 1.36
Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther (2011) 1.32
Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem (2010) 1.31
Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo. Oncogene (2003) 1.30
Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett (2009) 1.30